Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

cinrebafusp alfa (PRS-343)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pieris Pharmaceuticals, Servier

Drug class:

HER2 inhibitor, CD137 agonist

Related drugs:

‹

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

ALG.APV-527 (1)

PF-08046049 (1)

PF-05082566 (1)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2	PRS-343 Sensitive: C2 – Inclusion Criteria PRS-343 Sensitive : C2
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Urothelial Cancer	HER-2 positive	Urothelial Cancer	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3	PRS-343 Sensitive: C3 – Early Trials PRS-343 Sensitive : C3
HER-2 positive	Pancreatic Cancer	HER-2 positive	Pancreatic Cancer	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4
HER-2 positive	Melanoma	HER-2 positive	Melanoma	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4	PRS-343 Sensitive: C4 – Case Studies PRS-343 Sensitive : C4